OncRef

Clinical Trial: NCT06550141

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Status:

RECRUITING

Phase:

Phase 2

Lead Sponsor:Marcela V. Maus, M.D.,Ph.D.
Information Provided By:Massachusetts General Hospital
Last Update Posted:2026-10-06

Study Overview

Brief Summary

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL).

The research study involves the following study interventions:

  • Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy)
  • Axicabtagene Ciloleucel or Lisocabtagene Maraleucel
  • Emapalumab

Official Title

A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities

Conditions

Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma

Intervention / Treatment

  • Drug: Emapalumab
  • Drug: Cyclophosphamide
  • Drug: Fludarabine Phosphate
  • Drug: Axicabtagene Ciloleucel
  • Drug: Dexamethasone
  • Drug: Lisocabtagene maraleucel

Other Study ID Numbers

  • 24-317

Start Date (Actual)

2024-09-18

Primary Completion Date (Estimated)

2027-08-01

Study Completion Date (Estimated)

2028-08-01

Enrollment (Estimated)

28

Study Type

Interventional

Phase

Phase 2